Ultragenyx (RARE) Pharmaceutical announced the appointment of Eric Olson as Chief Business Officer and executive VP effective September 22, following the planned retirement of Thomas Kassberg. Olson will be responsible for leading the company’s business development, corporate development and alliance management functions. Before joining Ultragenyx, Olson served as CBO at Stoke Therapeutics, where he led all aspects of Stoke’s landmark ex-North America partnership with Biogen for zorevunersen.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
- Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
- Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
- Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
- Ultragenyx Reports Positive Phase 3 Gene Therapy Results